<?xml version='1.0' encoding='utf-8'?>
<document id="22370628"><sentence text="Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence."><entity charOffset="25-38" id="DDI-PubMed.22370628.s1.e0" text="dexamethasone" /><entity charOffset="60-69" id="DDI-PubMed.22370628.s1.e1" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.22370628.s1.e0" e2="DDI-PubMed.22370628.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22370628.s1.e0" e2="DDI-PubMed.22370628.s1.e1" /></sentence><sentence text="Concomitant usage of lapatinib, a cytochrome P450 (CYP) 3A4 substrate and dexamethasone, a CYP3A4 inducer, is a pharmacokinetic drug-drug interaction"><entity charOffset="21-30" id="DDI-PubMed.22370628.s2.e0" text="lapatinib" /><entity charOffset="74-87" id="DDI-PubMed.22370628.s2.e1" text="dexamethasone" /><pair ddi="false" e1="DDI-PubMed.22370628.s2.e0" e2="DDI-PubMed.22370628.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22370628.s2.e0" e2="DDI-PubMed.22370628.s2.e1" /></sentence><sentence text=" This combination may increase the formation of reactive lapatinib metabolites, which is potentially hepatotoxic"><entity charOffset="57-66" id="DDI-PubMed.22370628.s3.e0" text="lapatinib" /></sentence><sentence text=" This study aims to evaluate the clinical effect of dexamethasone on incidence of hepatotoxicity and to ascertain its in vitro role using a parallel cell culture model experimental setup"><entity charOffset="52-65" id="DDI-PubMed.22370628.s4.e0" text="dexamethasone" /></sentence><sentence text=" Clinical effects of dexamethasone on lapatinib-induced hepatotoxicity were evaluated in a nested case-control study based on 120 patient data obtained from our records"><entity charOffset="21-34" id="DDI-PubMed.22370628.s5.e0" text="dexamethasone" /><entity charOffset="38-47" id="DDI-PubMed.22370628.s5.e1" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.22370628.s5.e0" e2="DDI-PubMed.22370628.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22370628.s5.e0" e2="DDI-PubMed.22370628.s5.e1" /></sentence><sentence text=" For the in vitro experiment, metabolically competent transforming growth factor α mouse hepatocytes (TAMH) were treated with lapatinib and viabilities were compared in the presence or absence of dexamethasone"><entity charOffset="126-135" id="DDI-PubMed.22370628.s6.e0" text="lapatinib" /><entity charOffset="196-209" id="DDI-PubMed.22370628.s6.e1" text="dexamethasone" /><pair ddi="false" e1="DDI-PubMed.22370628.s6.e0" e2="DDI-PubMed.22370628.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22370628.s6.e0" e2="DDI-PubMed.22370628.s6.e1" /></sentence><sentence text=" After adjusting for confounders, patients receiving the combination were 4" /><sentence text="57 times (95% CI 1" /><sentence text="23-16" /><sentence text="88, p = 0" /><sentence text="02) more likely to develop hepatotoxicity and 3" /><sentence text="48 times (95% CI 1" /><sentence text="24-9" /><sentence text="80, p = 0" /><sentence text="02) more likely to develop a clinically important change in alanine aminotransferase than compared to the other group"><entity charOffset="60-67" id="DDI-PubMed.22370628.s15.e0" text="alanine" /></sentence><sentence text=" Treatment of TAMH cells with lapatinib and dexamethasone caused a further reduction in viability, as compared to treatment with lapatinib alone"><entity charOffset="30-39" id="DDI-PubMed.22370628.s16.e0" text="lapatinib" /><entity charOffset="44-57" id="DDI-PubMed.22370628.s16.e1" text="dexamethasone" /><entity charOffset="129-138" id="DDI-PubMed.22370628.s16.e2" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.22370628.s16.e0" e2="DDI-PubMed.22370628.s16.e0" /><pair ddi="false" e1="DDI-PubMed.22370628.s16.e0" e2="DDI-PubMed.22370628.s16.e1" /><pair ddi="false" e1="DDI-PubMed.22370628.s16.e0" e2="DDI-PubMed.22370628.s16.e2" /><pair ddi="false" e1="DDI-PubMed.22370628.s16.e1" e2="DDI-PubMed.22370628.s16.e1" /><pair ddi="false" e1="DDI-PubMed.22370628.s16.e1" e2="DDI-PubMed.22370628.s16.e2" /></sentence><sentence text=" At 5 μM lapatinib, the introduction of dexamethasone 20 μM produced a 59% decline in viability"><entity charOffset="40-53" id="DDI-PubMed.22370628.s17.e0" text="dexamethasone" /></sentence><sentence text=" This is the first study to document a clinically important interaction between lapatinib and dexamethasone, which associates with an increased occurrence of hepatotoxicity"><entity charOffset="80-89" id="DDI-PubMed.22370628.s18.e0" text="lapatinib" /><entity charOffset="94-107" id="DDI-PubMed.22370628.s18.e1" text="dexamethasone" /><pair ddi="false" e1="DDI-PubMed.22370628.s18.e0" e2="DDI-PubMed.22370628.s18.e0" /><pair ddi="false" e1="DDI-PubMed.22370628.s18.e0" e2="DDI-PubMed.22370628.s18.e1" /></sentence><sentence text=" The in vitro findings have provided substantiating evidence and insights on the role of dexamethasone in lapatinib-induced hepatotoxicity"><entity charOffset="89-102" id="DDI-PubMed.22370628.s19.e0" text="dexamethasone" /><entity charOffset="106-115" id="DDI-PubMed.22370628.s19.e1" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.22370628.s19.e0" e2="DDI-PubMed.22370628.s19.e0" /><pair ddi="false" e1="DDI-PubMed.22370628.s19.e0" e2="DDI-PubMed.22370628.s19.e1" /></sentence><sentence text="" /></document>